Search
Search Results
-
Decade-long WT1-specific CTLs induced by WT1 peptide vaccination
IntroductionThe peptide-based cancer vaccine targeting Wilms’ tumor 1 (WT1) is a promising immunotherapeutic strategy for hematological malignancies....
-
Obesity-related glomerulopathy is associated with elevated WT1 expression in podocytes
BackgroundThe prevalence of obesity is increasing worldwide at an alarming rate. In addition to the increased incidence of cardiovascular and...
-
WT1-related disorders: more than Denys-Drash syndrome
Historically, specific mutations in WT1 gene have been associated with distinct syndromes based on phenotypic characteristics, including Denys-Drash...
-
WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients
Wilms tumor 1 ( WT1 ) gene mutations are infrequent in myelodysplastic syndrome (MDS), but MDS with WT1 mutations (WT1 mut ) is considered high risk for...
-
WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
Measurable residual disease (MRD)-guided pre-emptive therapies are now widely used to prevent post-transplant hematological relapse in patients with...
-
A review of the genetic background in complicated WT1-related disorders
The Wilms tumor 1 ( WT1 ) gene was first identified in 1990 as a strong candidate for conferring a predisposition to Wilms tumor. The WT1 protein has...
-
Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide
We previously conducted a randomized phase II trial of OCV-501, a WT1 peptide presented by helper T cells, in elderly AML (acute myeloid leukemia)...
-
Evaluation of pathogenicity of WT1 intron variants by in vitro splicing analysis
BackgroundWilms tumor 1 ( WT1 ; NM_024426) causes Denys–Drash syndrome, Frasier syndrome, or isolated focal segmental glomerulosclerosis. Several WT1 ...
-
Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy
BackgroundWilms' tumor gene 1 ( WT1 ) mRNA quantification is a useful marker of measurable residual disease in acute myeloid leukemia (AML). However,...
-
A case of Potter sequence with WT1 mutation
Wilms tumor 1 ( WT1 ) is the causative gene of Denys–Drash syndrome and Frasier syndrome, and in most cases, kidney failure develops after birth. We...
-
High WT1 expression predicted induction chemotherapy failure in acute myeloid leukemia patients with non-favorable cytogenetic risk
The prognostic significance of WT1 expression at diagnosis in acute myeloid leukemia (AML) remains obscure, and subgroup analysis is the way for...
-
WT1 exon 10 missense variant in a pediatric patient with focal segmental glomerulosclerosis with embryonal hyperplasia
A 6-year-old boy was diagnosed with chromosomal abnormalities (48,XYY, + 21[11]/46,XY[19]) at 4 months of age after a physical examination revealed...
-
An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia
Wilms’ tumor 1 (WT1) is a promising tumor-associated antigen for cancer immunotherapy. We developed an oral protein vaccine platform composed of...
-
Molecular mechanism of Wilms’ tumor (Wt1) (+/−KTS) variants promoting proliferation and migration of ovarian epithelial cells by bioinformatics analysis
Epithelial ovarian cancer (EOC) is a gynecological disease with the highest mortality. With the lack of understanding of its pathogenesis, no...
-
Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1
Epithelial ovarian cancer is the most lethal of gynecological cancers. The therapeutic efficacy of chimeric antigen receptor (CAR) T cell directed...
-
Cytoplasmic WT1 in IgA nephropathy, an indicator of poor prognosis associated with mesangial/peri-mesangial C4d
BackgroundWe aimed to investigate the immuno-histochemical expression of C4d, ADAM10 and WT1 in kidney biopsies of immunoglobulin A nephropathy...
-
First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience
Wilms’ tumor 1 (WT1) protein is highly immunogenic and overexpressed in acute myeloid leukemia (AML), consequently ranked as a promising target for...
-
Isolated steroid-resistant nephrotic syndrome in a Chinese child carrying a de novo mutation in WT1 gene:a case report and literature review
BackgroundIsolated steroid-resistant nephrotic syndrome (ISRNS) is caused by mutations in the Wilms’ tumor-1 (WT1) gene, which encodes glomerular...
-
WT1 complete gonadal dysgenesis with membranoproliferative glomerulonephritis: case series and literature review
BackgroundIntronic WT1 mutations are usually causative of Frasier syndrome with focal segmental glomerulosclerosis as the characteristic...
-
Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy
We have previously revealed the overexpression of Wilms’ tumor gene 1 ( WT1 ) in malignant glioma and developed WT1 peptide vaccine cancer...
